Zealand Pharma A/S (ZEAL)
$17.59
Rating:
Recommendation:
Buy
| Symbol | ZEAL |
|---|---|
| Price | $17.59 |
| Beta | 1.336 |
| Volume Avg. | 0.00M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 9.93-32.12 |
| 1y Target Est | - |
| DCF Unlevered | ZEAL DCF -> | |
|---|---|---|
| DCF Levered | ZEAL LDCF -> | |
| ROE | -96.74% | Strong Sell |
| ROA | -49.24% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 84.87% | Buy |
| P/E | - | |
| P/B | 5.19 | Strong Buy |
Latest ZEAL news
About
Download (Excel)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.